Skip to Content
 
Center for International Blood and Marrow Transplant Research

GS19-02

Main Content

Graft failure in MDS and acute leukemia patients after allogeneic stem cell transplantation receiving post transplant cyclophosphamide.

Study #: GS19-02

Study Status: Published

Presentation(s)

2022, ASH (Oral)

Donor type does not impact late graft failure following reduced-intensity allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.

Citation

Hickey CL, Zhang M, Allbee-Johnson M, Romee R, Majhail NS, Malki M, Antin JH, Benjamin CL, Bredeson C, Chhabra S, Grunwald MR, Inamoto Y, Kanakry CG, Milano F, Soiffer RJ, Spellman SR, Solomon SR, Brunstein CG, Cutler C.

Transplantation and Cellular Therapy. 2025, Mar 01: 31(3): 31(3):174.e1-174.e12. doi: 10.1016/j.jtct.2024.12.021. Epub 2025, Jan 02. PMCID:PMC11875877.

PubMed

PMID: 39755256

Abstract